The pathogenesis of infant colic is poorly defined. Gut microbiota seems to be involved, supporting the potential therapeutic role of probiotics.
The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12® in infant colic: A randomised, double blind, placebo-controlled trial / Nocerino, R., De Filippis, F., Cecere, G., Marino, A., Micillo, M., Di Scala, C., de Caro, C., Calignano, A., Bruno, C., Paparo, L., Iannicelli, A.M., Cosenza, L., Maddalena, Y., Della Gatta, G., Coppola, S., Carucci, L., Ercolini, D., Berni Canani, R.. - In: ALIMENTARY PHARMACOLOGY & THERAPEUTICS. - ISSN 0269-2813. - (2020). [10.1111/apt.15561]
The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12® in infant colic: A randomised, double blind, placebo-controlled trial
Nocerino, Rita;De Filippis, Francesca;Marino, Antonio;Micillo, Maria;de Caro, Carmen;Calignano, Antonio;Bruno, Cristina;Paparo, Lorella;Cosenza, Linda;Coppola, Serena;Carucci, Laura;Ercolini, Danilo;Berni Canani, Roberto
2020
Abstract
The pathogenesis of infant colic is poorly defined. Gut microbiota seems to be involved, supporting the potential therapeutic role of probiotics.| File | Dimensione | Formato | |
|---|---|---|---|
|
Nocerino_et_al-2019-Alimentary_Pharmacology_&_Therapeutics (2).pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
1.02 MB
Formato
Adobe PDF
|
1.02 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
